Phase 1 Melanoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older
• People who have voluntarily agreed to take part by signing a consent form before any study procedures begin
• People who are able and willing to follow all study procedures for the full duration of the trial
• People who have an advanced solid tumour cancer that has been confirmed through a tissue sample (biopsy), has continued to grow or spread, and has already been treated with standard therapies — either without success or with intolerable side effects
• People whose general physical health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a medical scale called ECOG) at the start of the trial
• People who have been free of any other active cancer for at least 2 years
• People whose recent blood and lab test results fall within the ranges required by the trial
• Women who could become pregnant, and men, who agree to use adequate contraception during the trial

Who may not be able to join:

• People who have acute leukaemia or a type of blood cancer called chronic lymphocytic leukaemia (CLL)
• People who have significant heart disease, have had a heart attack in the past 6 months, or have an unstable irregular heartbeat
• People with certain heart rhythm abnormalities detected on a heart tracing (ECG), including a prolonged QT interval, a condition called congenital long QT syndrome, or other ECG abnormalities that the study doctor considers a safety concern
• People who have an active, uncontrolled bacterial, viral, or fungal infection that requires treatment with systemic medication within 7 days before the trial starts
• People who have an active autoimmune disease or another medical condition that requires ongoing use of steroid or immune-suppressing medications
• People with a known HIV, hepatitis B, or hepatitis C infection, unless certain specific conditions are met (confirm with trial site)
• People who have had a major organ transplant or a bone marrow transplant
• People who have cancer that has spread to the brain or spinal cord and is causing symptoms
• People with serious non-cancer illnesses (confirm with trial site for specifics)
• Women who are pregnant or currently breastfeeding
• People who have had major surgery within 28 days before the first dose of the study drug
• People who have received other cancer treatments within 4 weeks, or within 5 half-lives of the treatment (whichever is the shorter period), before starting this trial — though some exceptions may apply (confirm with trial site)
• People who have had a severe allergic reaction to a biological therapy in the past, which the study doctor believes may pose a safety risk
• People who have received radiation therapy to treat symptoms within 14 days before the trial starts
• People with an active substance abuse problem
• People who have previously had a severe immune-related side effect (Grade 3 or higher) from cancer immunotherapy

Important: Always verify eligibility with the trial site directly before applying.